Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 28, Issue 3, 2006, Pages 212-216

  Yanagihara, Katsunori ^a   Seki, Masafumi ^a   Izumikawa, Koichi ^a   Higashiyama, Yasuhito ^a   Miyazaki, Yoshitsugu ^a   Hirakata, Yoichi ^a   Tomono, Kazunori ^a   Mizuta, Yohei ^a   Tsukamoto, Kazuhiro ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

DX 619; MRSA; Pulmonary infection; Vancomycin intermediate Staphylococcus aureus

Indexed keywords

CYCLOPHOSPHAMIDE; DX 619; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BRONCHOPNEUMONIA; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG PARENCHYMA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; LUNG; MALE; METHICILLIN; METHICILLIN RESISTANCE; MICE; PNEUMONIA, STAPHYLOCOCCAL; PYRROLIDINES; QUINOLONES; SPECIFIC PATHOGEN-FREE ORGANISMS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33747096508     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.03.026     Document Type: Article

References (23)

1. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 41 (1997) 135-136
2. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 (1999) 493-501
3. Tanaka M., Yamazaki E., Chiba M., et al. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. Antimicrob Agents Chemother 46 (2002) 904-908
4. Inagaki H, Miyauchi RN, Itoh M, et al. DX-619, a novel Des-F(6)-quinolone: synthesis and in vitro antibacterial activity against multi-drug resistant Gram-positive bacteria. In: Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract F-1054.
5. Kaneko Y., Yanagihara K., Miyazaki Y., et al. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice. Antimicrob Agents Chemother 47 (2003) 3694-3698
6. Sawai T., Tomono K., Yanagihara K., et al. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 65 (1997) 466-471
7. Yanagihara K., Kaneko Y., Sawai T., et al. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection. Antimicrob Agents Chemother 46 (2002) 3288-3291
8. Yanagihara K., Okada M., Fukuda Y., et al. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. Chemotherapy 50 (2004) 260-264
9. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066
10. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb Mortal Wkly Rep 53 (2004) 322-323
11. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348 (2003) 1342-1347
12. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
13. Fuchs P.C., Barry A.L., and Brown S.D. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 44 (2000) 2880-2882
14. Malbruny B., Canu A., Bozdogan B., et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 2200-2207
15. Akins R.L., and Rybak M.J. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 44 (2000) 1925-1929
16. Cui L., Tominaga E., Neoh H.M., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
17. Weller T.M., Andrews J.M., Jevons G., and Wise R. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 49 (2002) 177-184
18. Lawrence L.E., Frosco M., Ryan B., et al. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob Agents Chemother 46 (2002) 191-195
19. Schaad U.B., and Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 30 (1992) 414-416
20. Szarfman A., Chen M., and Blum M.D. More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med 332 (1995) 193
21. Takayama S., Hirohashi M., Kato M., and Shimada H. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health 45 (1995) 1-45
22. Burkhardt J.E., Walterspiel J.N., and Schaad U.B. Quinolone arthropathy in animals versus children. Clin Infect Dis 25 (1997) 1196-1204
23. Lipsky B.A., and Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28 (1999) 352-364